JP7432361B2 - ヒトインスリンまたはそのアナログのアシル化誘導体 - Google Patents

ヒトインスリンまたはそのアナログのアシル化誘導体 Download PDF

Info

Publication number
JP7432361B2
JP7432361B2 JP2019503703A JP2019503703A JP7432361B2 JP 7432361 B2 JP7432361 B2 JP 7432361B2 JP 2019503703 A JP2019503703 A JP 2019503703A JP 2019503703 A JP2019503703 A JP 2019503703A JP 7432361 B2 JP7432361 B2 JP 7432361B2
Authority
JP
Japan
Prior art keywords
human insulin
zinc complex
acylated derivative
insulin analog
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019503703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526537A (ja
JP2019526537A5 (enExample
Inventor
徳玉 劉
宏偉 王
亮 趙
菲菲 王
翔 曾
涛 王
亜里 王
雨▲ルゥ▼ 戴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Pharmaceutical Co Ltd
Publication of JP2019526537A publication Critical patent/JP2019526537A/ja
Publication of JP2019526537A5 publication Critical patent/JP2019526537A5/ja
Priority to JP2022066071A priority Critical patent/JP2022095872A/ja
Application granted granted Critical
Publication of JP7432361B2 publication Critical patent/JP7432361B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2019503703A 2016-08-02 2017-08-01 ヒトインスリンまたはそのアナログのアシル化誘導体 Active JP7432361B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022066071A JP2022095872A (ja) 2016-08-02 2022-04-13 ヒトインスリンまたはそのアナログのアシル化誘導体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610625257 2016-08-02
CN201610625257.5 2016-08-02
CN201610779132 2016-08-31
CN201610779132.8 2016-08-31
PCT/CN2017/095377 WO2018024186A1 (zh) 2016-08-02 2017-08-01 一种人胰岛素或其类似物的酰化衍生物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022066071A Division JP2022095872A (ja) 2016-08-02 2022-04-13 ヒトインスリンまたはそのアナログのアシル化誘導体

Publications (3)

Publication Number Publication Date
JP2019526537A JP2019526537A (ja) 2019-09-19
JP2019526537A5 JP2019526537A5 (enExample) 2020-07-02
JP7432361B2 true JP7432361B2 (ja) 2024-02-16

Family

ID=61074099

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019503703A Active JP7432361B2 (ja) 2016-08-02 2017-08-01 ヒトインスリンまたはそのアナログのアシル化誘導体
JP2022066071A Pending JP2022095872A (ja) 2016-08-02 2022-04-13 ヒトインスリンまたはそのアナログのアシル化誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022066071A Pending JP2022095872A (ja) 2016-08-02 2022-04-13 ヒトインスリンまたはそのアナログのアシル化誘導体

Country Status (6)

Country Link
US (1) US10815287B2 (enExample)
EP (1) EP3495384A4 (enExample)
JP (2) JP7432361B2 (enExample)
CN (2) CN114478747B (enExample)
TW (1) TWI747929B (enExample)
WO (1) WO2018024186A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019149245A1 (zh) * 2018-02-01 2019-08-08 江苏恒瑞医药股份有限公司 含人胰岛素类似物的酰化衍生物的药物组合物及其制备方法
US20210032307A1 (en) 2018-02-09 2021-02-04 Jiangsu Hengrui Medicine Co., Ltd. Codon optimized precursor gene and signal peptide gene of human insulin analogue
KR20210016400A (ko) 2018-05-24 2021-02-15 지앙수 헨그루이 메디슨 컴퍼니 리미티드 재조합 인간 인슐린 또는 그 유사체의 전구체를 제조하는 방법
TW202039437A (zh) 2018-12-11 2020-11-01 法商賽諾菲公司 肽黏合劑
BR112022013009A2 (pt) 2019-12-30 2022-09-06 Gan & Lee Pharmaceuticals Co Ltd Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
CN116583531A (zh) * 2020-11-27 2023-08-11 江苏恒瑞医药股份有限公司 一种制备胰岛素或其类似物的酰化衍生物的方法
CN112939771A (zh) * 2021-01-28 2021-06-11 宁夏蓝博思化学技术有限公司 长链烷基二酸单叔丁酯的制备方法
CA3217734A1 (en) * 2021-05-24 2022-12-01 Baoye ZHENG A novel acylated insulin analog
WO2022268208A1 (zh) 2021-06-25 2022-12-29 甘李药业股份有限公司 含酰化胰岛素的药物组合物
WO2023143458A1 (zh) 2022-01-28 2023-08-03 甘李药业股份有限公司 酰化胰岛素
WO2025098457A1 (zh) 2023-11-07 2025-05-15 甘李药业股份有限公司 用于降糖的酰化胰岛素
CN117756914B (zh) * 2023-12-15 2024-09-03 瀚晖制药有限公司 依柯胰岛素的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009522231A (ja) 2005-12-28 2009-06-11 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
JP2015501819A (ja) 2011-12-15 2015-01-19 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ヒト・インスリン類似体及びそのアシル化誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ273285A (en) * 1993-09-17 1997-10-24 Novo Nordisk As Insulin derivatives and compositions thereof
CN1163574A (zh) * 1994-11-17 1997-10-29 伊莱利利公司 酰化的胰岛素类似物
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
US8003605B2 (en) * 2002-03-13 2011-08-23 Novo Nordisk A/S Minimising body weight gain in insulin treatment
ES2472421T3 (es) 2003-08-05 2014-07-01 Novo Nordisk A/S Nuevos derivados de insulina
AU2004261353B2 (en) * 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
WO2009022006A1 (en) * 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
HUE032284T2 (en) * 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
US8935928B2 (en) * 2011-10-10 2015-01-20 Lockheed Martin Corporation Integrated air-cycle refrigeration and power generation system
CN106496322A (zh) * 2015-09-07 2017-03-15 江苏恒瑞医药股份有限公司 人胰岛素或其类似物的酰化衍生物的制备方法
JP7523885B2 (ja) * 2016-02-05 2024-07-29 メモリアル スローン ケタリング キャンサー センター 幹細胞由来外胚葉系統前駆体を分化する方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009522231A (ja) 2005-12-28 2009-06-11 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
JP2015501819A (ja) 2011-12-15 2015-01-19 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ヒト・インスリン類似体及びそのアシル化誘導体

Also Published As

Publication number Publication date
WO2018024186A1 (zh) 2018-02-08
JP2019526537A (ja) 2019-09-19
EP3495384A4 (en) 2020-02-26
CN114478747A (zh) 2022-05-13
EP3495384A1 (en) 2019-06-12
CN108463468B (zh) 2022-03-04
TW201805300A (zh) 2018-02-16
CN114478747B (zh) 2024-06-14
CN108463468A (zh) 2018-08-28
TWI747929B (zh) 2021-12-01
US10815287B2 (en) 2020-10-27
US20190169257A1 (en) 2019-06-06
JP2022095872A (ja) 2022-06-28

Similar Documents

Publication Publication Date Title
JP2022095872A (ja) ヒトインスリンまたはそのアナログのアシル化誘導体
RU2531590C2 (ru) Аналоги глюкагоноподобного пептида-1 и их применение
US20230126068A1 (en) Insulin Derivative
JP5269767B2 (ja) インスリン誘導体
ES2611040T3 (es) Derivados de insulina
US9260503B2 (en) Multi-substituted insulins
CN119060162A (zh) 长效glp-1化合物
JP2022549730A (ja) エキセナチド類似体
JP2025525218A (ja) インクレチンアナログおよびその使用
TWI740099B (zh) 含人胰島素類似物的醯化衍生物的藥物組合物及其製備方法
WO2012016419A1 (zh) Glp-1衍生物及其应用
CN101684103B (zh) 1,2,4-三唑结构的化合物、其制备方法和用途
KR101496136B1 (ko) 글루카곤 유사 펩타이드-1 유사체 및 이의 용도
WO2007070563A2 (en) Stable solid forms of enterostatin
HK1255297B (en) Acylated derivative of human insulin or analogue thereof
HK1255297A1 (en) Acylated derivative of human insulin or analogue thereof
CN107365375A (zh) 一种对glp‑1受体具有高亲和性的多肽化合物及其制备方法和应用
CN101437849A (zh) 胰岛素衍生物
HK1162037B (en) Glucagon-like peptide-1 analogue and use thereof
HK1162526B (en) Glp-1 derivatives and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220413

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220413

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220506

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220510

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220708

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240205

R150 Certificate of patent or registration of utility model

Ref document number: 7432361

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150